UCB (WBO:UCB) Other Long Term Assets : €1,014 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is UCB Other Long Term Assets?

UCB's other long-term assets for the quarter that ended in Dec. 2023 was €1,014 Mil.

UCB's quarterly other long-term assets increased from Dec. 2022 (€974 Mil) to Jun. 2023 (€1,030 Mil) but then stayed the same from Jun. 2023 (€1,030 Mil) to Dec. 2023 (€1,014 Mil).

UCB's annual other long-term assets increased from Dec. 2021 (€893 Mil) to Dec. 2022 (€974 Mil) and increased from Dec. 2022 (€974 Mil) to Dec. 2023 (€1,014 Mil).

UCB Other Long Term Assets Historical Data

The historical data trend for UCB's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Other Long Term Assets Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

1,048.00

765.00

893.00

974.00

1,014.00

UCB Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long Term Assets	Get a 7-Day Free Trial															893.00	991.00	974.00	1,030.00	1,014.00

UCB Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

UCB (WBO:UCB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (WBO:UCB) Headlines

No Headlines